Andrew Paul Garner

Title: The Innovations of Andrew Paul Garner

Introduction

Andrew Paul Garner is a notable inventor based in Arlington, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting the epidermal growth factor receptor 3 (HER3). With a total of 4 patents to his name, Garner's work has the potential to impact the treatment of various diseases.

Latest Patents

Garner's latest patents focus on antibodies or fragments that interact with the HER family of receptors, specifically the HER3 receptor. One of his inventions involves antibodies that recognize a conformational epitope of the HER3 receptor, which inhibits both ligand-dependent and ligand-independent signal transduction. This innovation allows for ligand binding, such as neuregulin, while preventing ligand-induced activation of signal transduction. These antibodies can be utilized to treat diseases characterized by increased levels of HER3 expression, including esophageal cancer. Additionally, they may help decrease tissue weight or induce atrophy in tissues, such as prostate or uterine weights.

Career Highlights

Garner is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to further his research and development in the field of therapeutic antibodies. His contributions have been instrumental in advancing the understanding and treatment of conditions related to HER3.

Collaborations

Garner has collaborated with notable colleagues, including Elizabeth Anne Reisinger Sprague and Seth Alexander Ettenberg. These collaborations have enriched his research and expanded the scope of his innovations.

Conclusion

Andrew Paul Garner's work in developing antibodies for HER3 represents a significant advancement in biotechnology. His patents and collaborations highlight his commitment to improving healthcare through innovative solutions.